Related Experiment Video

Updated: Jul 3, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Oral anticoagulation in patients with cardiomyopathy or heart failure in sinus rhythm

P Pullicino1, J L P Thompson, J P Mohr

  • 1Kent Institute of Medicine and Health Sciences, University of Kent, Canterbury, Kent, UK. P.Pullicino@kent.ac.uk

Cerebrovascular Diseases (Basel, Switzerland)
|August 1, 2008
PubMed

Insights

Anticoagulation benefits are established in atrial fibrillation (AF), but evidence is lacking for cardiomyopathy (CM) in sinus rhythm. More research is needed to determine if antithrombotic drugs are beneficial for patients with CM.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) management includes anticoagulation, but evidence for cardiomyopathy (CM) in sinus rhythm is limited.
  • Cardiomyopathy (CM) poses a significant stroke risk, similar to historical AF risks.
  • Current understanding of stroke risk and antithrombotic indications in CM mirrors early AF research.

Purpose of the Study:

  • To review current knowledge on stroke risk in cardiomyopathy (CM).
  • To compare stroke risk and antithrombotic indications in CM with those in AF.
  • To highlight the need for evidence-based treatment guidelines for CM.

Main Methods:

  • Literature review of prospective randomized studies.
  • Analysis of risk factors for stroke in CM.
  • Comparison of antithrombotic agent indications in CM and AF.

Main Results:

  • Stroke risk and antithrombotic indications in CM are comparable to AF before dedicated treatment studies.
  • Existing data suggests a potential need for antithrombotic therapy in CM.
  • A knowledge gap exists regarding the efficacy and safety of antithrombotics in CM.

Conclusions:

  • Prospective randomized trials are essential to establish the role of antithrombotic drugs in CM.
  • Evidence-based guidelines are needed for antithrombotic therapy in cardiomyopathy patients.
  • Further research will clarify optimal stroke prevention strategies for CM.
Abstract

More Related Videos

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...